News
BLRX
1.120
+0.90%
0.010
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Benzinga · 2d ago
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BioLine Rx reported earnings per share of -15 cents. The company reported revenue of $4.80 million. This was above the analyst estimate for EPS of -22 cents. BioLine Rx was down 2% in after-hours trading on Thursday. The stock is down 7% in the past week.
Investorplace · 2d ago
Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism
TipRanks · 2d ago
BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M
Benzinga · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Stoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The company's, Q4 earnings came out yesterday. OpGen shares moved upwards by 77.6% and Praxis Precision Medicine (PRAX) shares increased by 21.38%. ABVC BioPharma (ABVC) and Sutro Biopharma (STRO) were among the losers.
Benzinga · 3d ago
GOEV, NBSE and FLGC among pre-market losers
GOEV, NBSE and FLGC among pre-market losers. NeuBase Therapeutics (NBSE) -58%. AppTech Payments Corp (APCX) announces proposed underwritten public offering. Bluebird bio (BLUE) reports Q4 results.
Seeking Alpha · 3d ago
Options Volatility and Implied Earnings Moves Today, March 26, 2024
TipRanks · 3d ago
BioLineRx Announces Major Commercial Milestones
TipRanks · 3d ago
Earnings Scheduled For March 26, 2024
Bluebird bio is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. AIM ImmunoTech is estimated to report earnings for its fourth quarter. Elbit Systems is projected to report. Quarterly earnings at $1.38 per share.
Benzinga · 3d ago
Pre-Market Earnings Report for March 26, 2024 : ABOS, BLRX, CGTX, DCTH, DOYU, ESLT, GDS, LLAP, MKC, SNX
NASDAQ · 3d ago
biolinerx Q4 2023 Earnings Preview
BioLineRx Ltd. (BLRX) is scheduled to announce Q4 earnings results on Tuesday, March 26th. The consensus EPS Estimate is -$0.22 and the consensus revenue estimate is $0.17M. Over the last 1 year, BLRX has beaten EPS estimates 25% of the time.
Seeking Alpha · 3d ago
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
TipRanks · 4d ago
Weekly Report: what happened at BLRX last week (0318-0322)?
Weekly Report · 4d ago
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 5d ago
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
BioLineRx Ltd. Will release its audited financial results for the year ended December 31, 2023 on March 26, 2024. Management to hold conference call at 08:30 a.m. EDT. The company is pursuing life-changing therapies in oncology and rare diseases.
Barchart · 03/20 06:00
Weekly Report: what happened at BLRX last week (0311-0315)?
Weekly Report · 03/18 10:20
Weekly Report: what happened at BLRX last week (0304-0308)?
Weekly Report · 03/11 10:18
Weekly Report: what happened at BLRX last week (0226-0301)?
Weekly Report · 03/04 10:20
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 02/29 20:46
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.